What is the recommended diagnostic evaluation and treatment approach for a child with suspected retinoblastoma?

Retinoblastoma Diagnosis and Treatment

All children with suspected retinoblastoma require immediate germline RB1 genetic testing (blood, buccal, or saliva) regardless of whether disease is unilateral or bilateral, and at-risk infants should undergo ophthalmologic examination within 24 hours of birth to maximize vision-sparing outcomes. 1

Diagnostic Evaluation

Clinical Presentation and Risk Stratification

The diagnostic approach hinges on recognizing hereditary versus sporadic disease patterns:

• Bilateral or unilateral multifocal disease = hereditary retinoblastoma (approximately 45% of all cases) 1
• Unilateral unifocal disease: At least 15% still have hereditary disease, particularly with young age at onset and macular tumor location 1
• Family history of retinoblastoma or retinoma automatically indicates hereditary disease 1

Critical pitfall: Tumor seeding can mimic true multifocal disease, especially with larger primary tumors and no family history—this requires careful ophthalmologic assessment 1

Genetic Testing Strategy

Germline RB1 testing is mandatory for all children with retinoblastoma to identify those requiring lifelong surveillance for subsequent malignant neoplasms (SMNs) 1. The testing approach should be:

1. Initial testing: Blood, buccal, or saliva samples for RB1 pathogenic variants
2. Understand laboratory limitations: Ensure the testing platform can detect mosaicism (present in 3-5% of hereditary cases) and provides complete RB1 gene coverage 1
3. If germline testing is negative but bilateral disease exists: Proceed with surveillance for hereditary disease regardless, as bilateral disease definitively represents hereditary retinoblastoma 1
4. Tumor tissue analysis (if enucleation performed): Identify both RB1 "hits" to guide germline testing interpretation and family member screening 1

Important nuance: Approximately 10% of sporadic unilateral tumors show RB1 promoter methylation, and 1.4% are driven by MYCN amplification rather than RB1 mutations—these MYCN-amplified tumors are more aggressive, occur at younger ages, and have distinct histology 1

Imaging Protocol

High-resolution MRI is the imaging modality of choice—CT should be avoided despite characteristic calcifications due to radiation exposure concerns in this population at high risk for secondary malignancies 2, 3. The 2025 ERIC guidelines specify:

• Timing: Within 2 weeks of diagnosis 3
• Technique: High-spatial-resolution contrast-enhanced MRI under general anesthesia 3
• Purpose: Pretreatment staging, tumor extension assessment, and confirmation of diagnosis when needed 4, 3

MRI findings typically show low-to-moderate T1 signal, moderate-to-high T2 signal, with significant enhancement post-contrast; heavily calcified tumors demonstrate long T1 and short T2 signals 4. CT (if absolutely necessary) shows posterior intraocular mass with high density (>100 HU) and calcifications 4.

Treatment Approach

Risk-Based Treatment Algorithm

The treatment strategy depends on laterality, stage, and risk factors:

For Bilateral Disease (Hereditary)

• Primary goal: Globe and vision preservation while achieving tumor control
• Current standard: Systemic chemotherapy has become established for primary intraocular disease 5
• Emerging approaches: Increasing use of intra-arterial chemotherapy for both naïve and recurrent eyes 6
• Focal therapies: Laser coagulation, thermotherapy, cryotherapy, and brachytherapy as adjuncts 5, 7
• Intravitreal chemotherapy: Increasingly used, particularly high-dose topotecan for vitreous seeds, anterior chamber tumor, and recurrent disease 6

For Unilateral Disease

The approach stratifies by histopathological risk after enucleation:

Low-risk (Stage I without high-risk features):

• No adjuvant therapy required 8
• 3-year event-free survival: 97% 8

High-risk (retrolaminar and/or scleral invasion):

• Adjuvant chemotherapy with alternating regimens:
  • Regimen 1: Cyclophosphamide (65 mg/kg/d with mesna), idarubicin (10 mg/m²/d), vincristine (0.05 mg/kg/d) × 4 cycles
  • Regimen 2: Carboplatin (500 mg/m²/d days 1-2), etoposide (100 mg/m²/d days 1-3) × 4 cycles 8
• This approach achieves 97% event-free survival but carries significant toxicity 8

Buphthalmos cases:

• Require both neoadjuvant and adjuvant chemotherapy for total of 8 cycles 8
• Higher risk profile with worse outcomes 8

Conservative Treatment for Intraocular Disease

When globe preservation is feasible:

• Systemic chemotherapy: Carboplatin, etoposide, vincristine (CEV regimen) for 4 cycles over 21-day intervals 7
• Focal therapy: Cryotherapy for peripheral lesions, argon laser photocoagulation for posterior lesions 7
• Treatment tolerance: Generally well-tolerated with minimal adverse effects in young infants 7

Prognostic imaging factors that predict better outcomes with conservative therapy include: greater distance from optic disc, smaller tumor diameter, absence of implantation nodules, endogenous growth pattern, smaller retinal detachment, absence of clinical high-risk factors, no vitreous hemorrhage, no globe shrinkage, and smaller calcification volume 4. The distance from optic disc, clinical high-risk factors, and tumor growth pattern are independent prognostic factors 4.

Surveillance Requirements

For At-Risk Infants

Ophthalmologic examination within 24 hours of birth for all at-risk infants (those with affected parent or sibling) to maximize visual sparing through early tumor detection 1

For Children of Affected Parents

Frequent screening for all children of a parent with retinoblastoma—whether unilateral or bilateral—until germline testing clarifies hereditary status 1. This represents an important update from previous guidelines that recommended less frequent screening for children of unilateral disease parents.

For Hereditary Cases

• Intraocular surveillance: Close ophthalmologic follow-up throughout childhood given high penetrance (>90% risk) 1
• SMN surveillance: Lifelong monitoring required as SMNs remain a major cause of death, particularly sarcomas and melanomas 1
• Radiation exposure: Avoid when possible as it substantially increases SMN risk, especially when given before age 1 year 1, 9

For Bilateral Disease with Negative Germline Testing

Continue surveillance for hereditary disease regardless of negative genetic testing, as bilateral disease definitively represents hereditary retinoblastoma and negative results may reflect undetected mosaicism or testing limitations 1

Key Clinical Considerations

Chromosomal 13q deletions including RB1 (13q14.2) cause additional concerns beyond retinoblastoma: developmental delay, congenital anomalies, and characteristic facial features. Larger deletions (>1MB) including MED4 paradoxically result in reduced penetrance of intraocular tumors 1

Parent-of-origin effects: Some hypomorphic RB1 alleles show differential expression with higher retinoblastoma risk when inherited from the father 1

Cure rates: When tumor is confined to the eye, cure rates exceed 95% in developed countries with access to multimodality therapy 5, 6. However, metastatic disease carries poor prognosis 5